Relevance of aneuploidy for cancer therapies targeting the spindle assembly checkpoint and KIF18A

Yael Cohen-Sharir, Uri Ben-David*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Aneuploidy, a common feature of cancer cells, results in increased sensitivity to the inhibition of the spindle assembly checkpoint (SAC) and the mitotic motor protein Kinesin Family Member 18A (KIF18A). We discuss the importance of drugs targeting SAC core members and KIF18A. We stress the need to assess the sensitivity to this class of drugs at appropriate time points, and propose that aneuploidy could serve as a biomarker to stratify patients for SAC-targeting treatments.

Original languageEnglish
Article number1915075
JournalMolecular and Cellular Oncology
Volume8
Issue number3
DOIs
StatePublished - 2021

Funding

FundersFunder number
DoD CDMRPCA191148
Richard Eimert Research Fund on Solid Tumors
Israel Cancer Research Fund
Israel Cancer Association20200111
Tel Aviv University
Azrieli Foundation

    Keywords

    • Aneuploidy
    • KIF18A
    • SAC
    • cancer
    • cancer therapies
    • spindle assembly checkpoint

    Fingerprint

    Dive into the research topics of 'Relevance of aneuploidy for cancer therapies targeting the spindle assembly checkpoint and KIF18A'. Together they form a unique fingerprint.

    Cite this